Literature DB >> 16895750

Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis.

Adla B Hassan1, Maryam Fathi, Maryam Dastmalchi, Ingrid E Lundberg, Leonid Padyukov.   

Abstract

Our aim was to investigate presence of tumour necrosis factor (TNF) and interleukin (IL)-10 in serum and their relation to different genotypes as well as to clinical and laboratory phenotypes in patients with polymyositis and dermatomyositis. In 65 patients with poly- or dermatomyositis the inflammatory cytokine balance was evaluated by the assessing absolute levels as well as the ratio between TNF and IL-10 in serum. These levels were correlated to the G-308A TNFA, G-1087A IL10 and G915C TGFB1 gene polymorphisms and haplotype frequencies, gender, autoantibody profiles and clinical manifestations. Increased serum levels of TNF and IL-10 were observed in patients compared to controls. A significantly higher TNF:IL-10 ratio was detected in female poly- and dermatomyositis patients carrying the TNF2 allele compared to female patients with the TNF1/TNF1 genotype (median+/-IQR 1.513+/-0.0.679 vs. 0.950+/-1.173, p=0.021). This ratio was also significantly higher in patients with the extended MICA5.1/TNF2/TNFa2/DRB1*03 haplotype compared to patients lacking this haplotype. A significantly higher TNF:IL-10 ratio was recorded in sera of patients with anti-Ro52 (1.513+/-1.275 and 1.276+/-0.671, positive vs. negative, p=0.010) antibodies and in women with anti-Jo-1 (1.919+/-0.918 and 1.281+/-0.790, positive vs. negative, p=0.041). Our data suggest that a genetically programmed cytokine imbalance exists in patients with poly- or dermatomyositis and that this imbalance is related to the presence of disease-associated autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16895750     DOI: 10.1016/j.jaut.2006.06.003

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

Review 1.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 2.  Pathogenesis of dermatomyositis: role of cytokines and interferon.

Authors:  Lily Kao; Lorinda Chung; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

3.  Genetic risk and protective factors for the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Frederick W Miller
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 4.  Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2011-01-21       Impact factor: 6.682

5.  Associations between TNF-α-308A/G polymorphism and susceptibility with dermatomyositis: a meta-analysis.

Authors:  Si Chen; Qian Wang; Ziyan Wu; Qingjun Wu; Ping Li; Yuan Li; Jing Li; Chuiwen Deng; Chanyuan Wu; Lei Gao; Fengchun Zhang; Yongzhe Li
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

6.  Increased Risk of Herpes Zoster Following Dermatomyositis and Polymyositis: A Nationwide Population-Based Cohort Study.

Authors:  Shin-Yi Tsai; Cheng-Li Lin; Ying-Chi Wong; Tse-Yen Yang; Chien-Feng Kuo; Jiung-Mou Cheng; Jyh-Seng Wang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

7.  Apparent Hypothalamic-Pituitary-Adrenal Axis Suppression via Reduction of Interleukin-6 by Glucocorticoid Therapy in Systemic Autoimmune Diseases.

Authors:  Natsuki Fujio; Shotaro Masuoka; Kotaro Shikano; Natsuko Kusunoki; Toshihiro Nanki; Shinichi Kawai
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.